Zobrazeno 1 - 10
of 22 454
pro vyhledávání: ''
Publikováno v:
American Journal of Therapeutics. 29:e611-e615
Background Infliximab (IFX) has been shown to be effective rescue therapy for hospitalized ulcerative colitis patients failing intravenous (IV) corticosteroids (CS). There is little evidence, however, describing its use in similar hospitalized Crohn'
Autor:
Marion G. Peters, Douglas T. Dieterich, Harry L.A. Janssen, Ira M. Jacobson, Mindie H. Nguyen, Paul J. Martin, Daryl T.-Y. Lau
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:1766-1775
Background and Aims Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with
Autor:
Alessandro Armuzzi, Tommaso Schepis, Antonio Gasbarrini, Franco Scaldaferri, Daniela Pugliese, Flavio Caprioli, Giuseppe Privitera, Luigi Larosa, Sara Onali
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1483-e1487
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receivi
Autor:
Pablo Navarro, Marta Maia Bosca-Watts, Joan Tosca, Miguel Minguez, Marta Revaliente, Rosario Anton, Ana Sanahuja, Carles Suria
Publikováno v:
Gastroenterologia Y Hepatologia
La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la inci
Autor:
Julia Nazco-Casariego, Laura Ramos, Fernando Gutiérrez-Nicolás, Raquel De La Barreda, Enrique Quintero, Inmaculada Alonso-Abreu, Javier Ramos-Rodríguez, Marta Carrillo-Palau
Publikováno v:
Gastroenterología y Hepatología (English Edition). 45:335-341
Nonadherence to medication is common in patients with inflammatory bowel disease (IBD) and can result in disease complications, therapy escalation, and the need for corticosteroids. The aim of this study was to assess the adherence to self-administer
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1192-e1195
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clin
Autor:
Markus Cornberg, Christoph Höner zu Siederdissen, George N. Dalekos, Fabien Zoulim, Milan J. Sonneveld, Wai-Kay Seto, Nicole S. Erler, Heiner Wedemeyer, Thomas Berg, Ivana Carey, Jun Yong Park, Kosh Agarwal, Yasuhito Tanaka, Sang Hoon Ahn, Benjamin Maasoumy, Apichat Kaewdech, Teerha Piratvisuth, Maria Buti, Man-Fung Yuen, George V. Papatheodoridis, Andre Boonstra, Margarita Papatheodoridi, Florian van Bömmel
Publikováno v:
Clinical Gastroenterology and Hepatology, 20(4), e784-e793. W.B. Saunders
Background & Aims: Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg
Publikováno v:
Gut and Liver. 16:147-156
Although Helicobacter pylori infection is the most important causative factor for gastric cancer (GC), H. pylori eradication alone does not completely eliminate the GC risk. In addition to H. pylori eradication, other risk factors for GC should be id
Autor:
Anil Arora, Nishant Verma, Prateek Shivshankar Padole, Praveen Sharma, Prakash Chand, Ashok Kumar
Publikováno v:
J Clin Exp Hepatol
BACKGROUND: Saroglitazar is a novel, dual peroxisome proliferator-activated receptors-α/γ agonist and is being investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: Consecutive overweight (body mass index
Autor:
Marjolein Y.V. Homs, Florian E. Buisman, Adriaan Moelker, Dirk J. Grünhagen, W.F. Filipe, B. Groot Koerkamp, Boris Galjart, Cees Verhoef
Publikováno v:
HPB. 24(3):299-308
Background The practice of adjuvant hepatic arterial infusion chemotherapy (HAIC) for colorectal liver metastasis (CRLM) varies widely. This meta-analysis investigates the effectiveness of adjuvant HAIC and the influence of variations in HAIC treatme